anti-miR-10b Nanodrug for Treatment of Breast Cancer Metastasis: Study in Companion Animals

用于治疗乳腺癌转移的抗 miR-10b 纳米药物:伴侣动物研究

基本信息

  • 批准号:
    10659027
  • 负责人:
  • 金额:
    $ 55.69万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-07-13 至 2026-06-30
  • 项目状态:
    未结题

项目摘要

ABSTRACT Nanoparticle-based technologies including theranostic nanomedicine are fast developing areas of biomedical research offering unprecedented potential for cancer treatment. This application is designed to bring this potential to translational level and investigate the application of our novel image-capable nanodrug for treatment of metastatic breast cancer in a large animal model. Breast cancer metastasis is the main cause of mortality among breast cancer patients, and for that reason the specific aims of this application respond to an unmet clinical need. This proposed strategy is based on our discovery that the survival of metastatic cells crucially depends on the high expression of microRNA-10b (miR-10b) and that miR-10b is responsible for metastatic cell viability. With this discovery it became possible to kill these cells at metastatic sites by inhibiting miR-10b. This is achieved using a nanodrug composed of anti-miR-10b antagomirs conjugated to dextran-coated magnetic nanoparticles (termed MN-anti-miR10b). These nanoparticles serve as delivery vehicles for the antagomirs. Also, the magnetic properties of these nanoparticles allow for monitoring of their delivery in vivo using magnetic resonance imaging (MRI), which is an added value for clinical implementation of this therapeutic approach. In pre-clinical studies in mice, we showed delivery of MN-anti-miR-10b to established metastases in the lymph nodes, lungs, bone and brain. Pilot studies in companion cats showed the delivery of the nanodrug to the metastatic lesions after intravenous injection. Therapeutic studies in the murine model of human MDA-MB-231 TNBC showed that delivery of MN-anti-miR10b to lymph nodes with established metastases resulted in arrest of metastatic growth by halting tumor cell proliferation and triggering apoptosis. When combined with a low-dose chemotherapy, MN-anti-miR10b caused complete elimination of lymph node metastases with no evidence of systemic toxicity after just four weekly treatments. Next, we showed the utility of the nanodrug in combination with low-dose chemotherapy for treatment of established lung metastases corresponding to Stage IV of human disease in immunocompetent murine model (4T1). We found that six weekly treatments were sufficient to cause complete regression of pre-existing lung metastases with no further dissemination to other organs in the remaining animals. With an outlook to clinical translation of our studies, in this application we propose to test our nanodrug strategy in large animals with spontaneous metastatic breast cancer (companion cats). Studies proposed here will serve as a necessary step towards first-in-human trials, because they will prove successful delivery of the nanodrug in large animals, which are anatomically and physiologically distinct from the murine models tested to date. Furthermore, these studies will provide us with additional information on PK/PD parameters in a large animal model. Finally, therapeutic studies in spontaneous models will mimic those in humans where development of metastases is largely unpredicted in terms of time and location. We expect that these studies will serve as the final step in the pre-clinical stage of this project, which will next move to the pre-IND stage.
摘要 基于纳米颗粒的技术,包括治疗诊断纳米医学,是生物医学的快速发展领域。 为癌症治疗提供前所未有的潜力。该应用程序旨在将此 潜在的翻译水平,并研究我们的新的成像能力纳米药物的治疗应用 转移性乳腺癌在一个大的动物模型。乳腺癌转移是导致死亡的主要原因 在乳腺癌患者中,并且由于该原因,本申请的特定目的响应于未满足的 临床需要这一策略的提出是基于我们的发现,即转移性细胞的存活至关重要, 依赖于microRNA-10 b(miR-10 b)的高表达,miR-10 b负责转移性细胞 生存能力随着这一发现,通过抑制miR-10 b在转移部位杀死这些细胞成为可能。这 使用由与葡聚糖包被的磁性载体缀合的抗miR-10 b寡核苷酸组成的纳米药物来实现 纳米颗粒(称为MN-抗-miR 10 b)。这些纳米颗粒作为递送载体用于Escheromir。还有, 这些纳米颗粒的磁性允许使用磁性纳米颗粒监测它们在体内的递送 磁共振成像(MRI),这是该治疗方法的临床实施的附加值。在 在小鼠的临床前研究中,我们显示MN-抗-miR-10 b递送至淋巴中已建立的转移灶, 淋巴结,肺,骨骼和大脑在伴侣猫中的初步研究表明,将纳米药物递送到 静脉注射后转移病灶。人MDA-MB-231鼠模型中的治疗研究 TNBC显示MN-抗miR 10 b递送至具有已确定转移的淋巴结导致miR 10 b的抑制。 通过停止肿瘤细胞增殖和触发凋亡来转移生长。当与低剂量的 化疗后,MN-抗miR 10 b引起淋巴结转移完全消除,没有证据表明 在四周治疗后出现全身毒性。接下来,我们展示了纳米药物与 低剂量化疗用于治疗已确定的肺转移,对应于人类IV期 免疫活性鼠模型(4 T1)中的疾病。我们发现每周六次的治疗足以引起 预先存在的肺转移完全消退,没有进一步扩散到其他器官, 剩下的动物。 展望临床翻译我们的研究,在这个应用程序中,我们建议测试我们的纳米药物策略 在患有自发性转移性乳腺癌的大型动物(伴侣猫)中。这里提出的研究将有助于 这是迈向首次人体试验的必要一步,因为它们将证明纳米药物的成功递送, 大型动物,其在解剖学和生理学上不同于迄今为止测试的鼠模型。 此外,这些研究将为我们提供关于大型动物PK/PD参数的额外信息 模型最后,在自发模型中的治疗研究将模仿人类中的那些, 转移在时间和位置上很大程度上是不可预测的。我们希望这些研究将作为 本项目临床前阶段的最后一步,下一步将进入IND前阶段。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Case report: MicroRNA-10b as a therapeutic target in feline metastatic mammary carcinoma and its implications for human clinical trials.
  • DOI:
    10.3389/fonc.2022.959630
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    4.7
  • 作者:
    Savan, N. Anna;Saavedra, Paulo Vilar;Halim, Alan;Yuzbasiyan-Gurkan, Vilma;Wang, Ping;Yoo, Byunghee;Kiupel, Matti;Sempere, Lorenzo;Medarova, Zdravka;Moore, Anna
  • 通讯作者:
    Moore, Anna
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ANNA MOORE其他文献

ANNA MOORE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ANNA MOORE', 18)}}的其他基金

Novel Prostate cancer therapy based on m-aconitase inhibition
基于 m-乌头酸酶抑制的新型前列腺癌疗法
  • 批准号:
    10435673
  • 财政年份:
    2022
  • 资助金额:
    $ 55.69万
  • 项目类别:
Novel Prostate cancer therapy based on m-aconitase inhibition
基于 m-乌头酸酶抑制的新型前列腺癌疗法
  • 批准号:
    10580844
  • 财政年份:
    2022
  • 资助金额:
    $ 55.69万
  • 项目类别:
Large Animal Facility for Imaging and Image-guided Therapies at MSU
密歇根州立大学用于成像和图像引导治疗的大型动物设施
  • 批准号:
    10373769
  • 财政年份:
    2021
  • 资助金额:
    $ 55.69万
  • 项目类别:
Therapy for Metastatic breast cancer based on micro RNA silencing
基于微小RNA沉默的转移性乳腺癌治疗
  • 批准号:
    10434241
  • 财政年份:
    2021
  • 资助金额:
    $ 55.69万
  • 项目类别:
Therapy for Metastatic breast cancer based on micro RNA silencing
基于微小RNA沉默的转移性乳腺癌治疗
  • 批准号:
    10489811
  • 财政年份:
    2021
  • 资助金额:
    $ 55.69万
  • 项目类别:
anti-miR-10b Nanodrug for Treatment of Breast Cancer Metastasis: Study in Companion Animals
用于治疗乳腺癌转移的抗 miR-10b 纳米药物:伴侣动物研究
  • 批准号:
    10450168
  • 财政年份:
    2021
  • 资助金额:
    $ 55.69万
  • 项目类别:
anti-miR-10b Nanodrug for Treatment of Breast Cancer Metastasis: Study in Companion Animals
用于治疗乳腺癌转移的抗 miR-10b 纳米药物:伴侣动物研究
  • 批准号:
    10265643
  • 财政年份:
    2021
  • 资助金额:
    $ 55.69万
  • 项目类别:
Therapy for Metastatic breast cancer based on micro RNA silencing
基于微小RNA沉默的转移性乳腺癌治疗
  • 批准号:
    9979793
  • 财政年份:
    2018
  • 资助金额:
    $ 55.69万
  • 项目类别:
Therapy for Metastatic breast cancer based on micro RNA silencing
基于微小RNA沉默的转移性乳腺癌治疗
  • 批准号:
    9753181
  • 财政年份:
    2018
  • 资助金额:
    $ 55.69万
  • 项目类别:
siRNA Protection of Composite Islet Kidney Transplant in Baboons
狒狒复合胰岛肾移植的 siRNA 保护
  • 批准号:
    8970851
  • 财政年份:
    2015
  • 资助金额:
    $ 55.69万
  • 项目类别:

相似海外基金

Linking Epidermis and Mesophyll Signalling. Anatomy and Impact in Photosynthesis.
连接表皮和叶肉信号传导。
  • 批准号:
    EP/Z000882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 55.69万
  • 项目类别:
    Fellowship
Digging Deeper with AI: Canada-UK-US Partnership for Next-generation Plant Root Anatomy Segmentation
利用人工智能进行更深入的挖掘:加拿大、英国、美国合作开发下一代植物根部解剖分割
  • 批准号:
    BB/Y513908/1
  • 财政年份:
    2024
  • 资助金额:
    $ 55.69万
  • 项目类别:
    Research Grant
Simultaneous development of direct-view and video laryngoscopes based on the anatomy and physiology of the newborn
根据新生儿解剖生理同步开发直视喉镜和视频喉镜
  • 批准号:
    23K11917
  • 财政年份:
    2023
  • 资助金额:
    $ 55.69万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetics of Extreme Phenotypes of OSA and Associated Upper Airway Anatomy
OSA 极端表型的遗传学及相关上呼吸道解剖学
  • 批准号:
    10555809
  • 财政年份:
    2023
  • 资助金额:
    $ 55.69万
  • 项目类别:
computational models and analysis of the retinal anatomy and potentially physiology
视网膜解剖学和潜在生理学的计算模型和分析
  • 批准号:
    2825967
  • 财政年份:
    2023
  • 资助金额:
    $ 55.69万
  • 项目类别:
    Studentship
Computational comparative anatomy: Translating between species in neuroscience
计算比较解剖学:神经科学中物种之间的翻译
  • 批准号:
    BB/X013227/1
  • 财政年份:
    2023
  • 资助金额:
    $ 55.69万
  • 项目类别:
    Research Grant
Doctoral Dissertation Research: Social and ecological influences on brain anatomy
博士论文研究:社会和生态对大脑解剖学的影响
  • 批准号:
    2235348
  • 财政年份:
    2023
  • 资助金额:
    $ 55.69万
  • 项目类别:
    Standard Grant
Development of a novel visualization, labeling, communication and tracking engine for human anatomy.
开发一种新颖的人体解剖学可视化、标签、通信和跟踪引擎。
  • 批准号:
    10761060
  • 财政年份:
    2023
  • 资助金额:
    $ 55.69万
  • 项目类别:
Understanding the functional anatomy of nociceptive spinal output neurons
了解伤害性脊髓输出神经元的功能解剖结构
  • 批准号:
    10751126
  • 财政年份:
    2023
  • 资助金额:
    $ 55.69万
  • 项目类别:
Anatomy and functions of LTP interactomes and their relationship to small RNA signals in systemic acquired resistance
LTP相互作用组的解剖和功能及其与系统获得性耐药中小RNA信号的关系
  • 批准号:
    BB/X013049/1
  • 财政年份:
    2023
  • 资助金额:
    $ 55.69万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了